Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Warby ParkerWRBY -0.19%69 EV-to-EBITDA is 58.57 as of Aug. 11, 2026. GuruFocus rates WRBY with a GF Score™ of 69/100 and a GF Value™ of $21.61 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 516 Medical Devices & Instruments companies, Warby Parker ranks worse than 90.89% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Warby Parker's enterprise value is $3,222.8 Mil.
Warby Parker's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $55.0 Mil. Therefore, Warby Parker's EV-to-EBITDA for today is 58.57.
The historical rank and industry rank for Warby Parker's EV-to-EBITDA or its related term are showing as below:
WRBY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -142.67 Med: -15.5 Max: 1824.82
Current: 58.57
During the past 7 years, the highest EV-to-EBITDA of Warby Parker was 1824.82. The lowest was -142.67. And the median was -15.50.
WRBY's EV-to-EBITDA is ranked worse than 90.89% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 14.81
vs WRBY: 58.57
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Warby Parker's PE Ratio (TTM) for today is calculated as:
Warby Parker's share price for today is $26.41.
Warby Parker's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.070.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Warby Parker's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Warby Parker's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Warby Parker EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Warby Parker's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Warby Parker's EV-to-EBITDA falls into.
Warby Parker's current Enterprise Value is $3,222.8 Mil.
Warby Parker's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $55.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Warby Parker (WRBY) has a EV-to-EBITDA of 58.57 as of Aug. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Warby Parker. According to the industry distribution chart, Warby Parker ranks #469 out of 516 companies in the Medical Devices & Instruments industry, placing it in the top 90.9%.
Is Warby Parker's EV-to-EBITDA too high?
Warby Parker's current EV-to-EBITDA is 58.57. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.81. Warby Parker's value of 58.57 is 295.5% above this industry median. Based on the distribution chart, Warby Parker ranks #469 out of 516 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Warby Parker has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Warby Parker's EV-to-EBITDA compare to XRAY and LMAT?
According to the Medical Devices & Instruments industry distribution chart, Warby Parker ranks #469 out of 516 companies for EV-to-EBITDA. This places Warby Parker in the lower half of its industry. The industry median EV-to-EBITDA is 14.81. Warby Parker's value of 58.57 is 295.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.81, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Warby Parker's current EV-to-EBITDA of 58.57 is 295.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Warby Parker. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Warby Parker's current EV-to-EBITDA is 58.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Warby Parker stock overvalued right now?
Based on GuruFocus' analysis, Warby Parker (WRBY) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.61, compared to a current price of $26.41 — trading 22.2% above its estimated fair value. The current EV-to-EBITDA is 58.57 and 295.5% above the Medical Devices & Instruments industry median of 14.81. Warby Parker's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Warby Parker (WRBY), the current EV-to-EBITDA is 58.57 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Warby Parker (WRBY) Overvalued in 2026?
Based on GuruFocus' analysis, Warby Parker stock appears to be overvalued.
The current stock price of $26.41 is trading 22.2% above its estimated GF Value™ of $21.61.
GuruFocus considers Warby Parker to be Modestly Overvalued.
Key valuation signals for WRBY:
EV-to-EBITDA: 58.57
GF Value™: $21.61 vs. price of $26.41 (22.2% above fair value)
Industry Position: 295.5% above the Medical Devices & Instruments median (#469 of 516)
No single metric tells the full story. See the WRBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The Company provides holistic vision care by offering eyewear, contacts, and eye care directly to consumers through its integrated, omnichannel platform. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
69GF Score
Get the complete analysis for WRBY
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WRBY has been successfully added to your 
